EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome

Marta Torres-Ferrus iD, Victor J Gallardo iD, Alicia Alpuente iD, Edoardo Caronna iD, Eulalia Giné-Ciprés iD, Patricia Pozo-Rosich iD

European Journal of Neurology · 2023

DOI: 10.1111/ene.15816 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Marta Torres-Ferrus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The response pattern to monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual level. This study was undertaken to describe patterns of start and consistency of the response to anti‐CGRP MAbs during the first 6 months of treatment and the association with baseline clinical characteristics. Methods This is a prospective clinical cohort observational study. We included migraine patients treated with erenumab or galcanezumab evaluated at baseline and after 3 and 6 months (M3, M6) of treatment. The response was categorized according to reduction in monthly headache days (MHD): Sustained‐response (SustainedR, ≥50% at M3 and M6), Short‐Response (ShortR, M3 ≥50% and M6

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideMigraine DisordersHumansProspective StudiesAntibodies, MonoclonalHeadacheTreatment Outcome

Stichwörter der Autor:innen

calcitonin gene-related peptideerenumabgalcanezumabmigrainemigraine preventionmonoclonal antibodiesreal-world

Substanzen

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Headache and Neurological Pain Research Group, Departament de Medicina, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Marta Torres-Ferrus, Victor J Gallardo, Alicia Alpuente, Edoardo Caronna, Eulalia Giné-Ciprés, Patricia Pozo-Rosich

Zitieren

APA

Torres-Ferrus, M., Gallardo, V. J., Alpuente, A., Caronna, E., Giné-Ciprés, E., & Pozo-Rosich, P. (2023). Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome. European Journal of Neurology. https://doi.org/10.1111/ene.15816

Vancouver

Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Giné-Ciprés E, Pozo-Rosich P. Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome. European Journal of Neurology. 2023. doi:10.1111/ene.15816

BibTeX
@article{TorresFerrus2023,
  author = {Torres-Ferrus, Marta and Gallardo, Victor J and Alpuente, Alicia and Caronna, Edoardo and Giné-Ciprés, Eulalia and Pozo-Rosich, Patricia},
  title = {Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15816}
}
Kostenlos starten →